Serina Therapeutics, Inc.SERNYSE
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -51.72% | -100.45% | -100.00% | +0.00% | -100.00% |
| Gross Profit Growth | +0.00% | -100.45% | +0.00% | +0.00% | -221.43% |
| EBITDA Growth | -23.62% | -317.27% | +0.00% | -217.55% | -414.23% |
| Operating Income Growth | +0.00% | -2402.49% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -19.52% | -360.70% | +0.00% | -223.90% | -425.18% |
| EPS Growth | -80.00% | +0.00% | +0.00% | -204.92% | -375.00% |
| EPS Diluted Growth | -43.48% | +0.00% | +0.00% | -225.49% | -438.46% |
| Weighted Average Shares Growth | +304.16% | +720.30% | +249.68% | +17.50% | +16.81% |
| Weighted Average Shares Diluted Growth | +41.76% | +896.39% | +249.68% | -1.51% | -3.83% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -3892.56% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -9107.84% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -80.28% | +0.00% | -100.00% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -39.11% | -25.02% | -38.00% | -16.50% | +66.95% |
| Book Value per Share Growth | +0.00% | -98.10% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +416.76% | -92.75% | -97.99% | -98.45% | -72.10% |
| R&D Expense Growth | +339.09% | +160.75% | +166.82% | +97.74% | +50.48% |
| SG&A Expenses Growth | +227.45% | +63.99% | +141.84% | +9.47% | -5.84% |